Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 60 Pages
|Crestor(急性冠狀動脈症候群)- 預測與市場分析 Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023|
|出版日期: 2014年07月31日||內容資訊: 英文 60 Pages||
GlobalData has released its new PharmaPoint Drug Evaluation report, "Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023". The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins - is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.
Crestor remains the only branded statin in the 7MM covered in this forecast. It is the most potent of all of the HMG-CoA reductase inhibitors. Crestor faces steep competition from the generic statins, especially atorvastatin, which can boast a low cost and a preponderance of clinical trial data in support of its efficacy and safety. Nevertheless, when Crestor's patent expires in the US in 2016 and in the EU and Japan in 2017, the use of rosuvastatin is likely to increase, but the gain in sales is likely to be allocated to the new generic options.